Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, S. Pignata, N. Colombo, Ursula Denison, Ignace Vergote, Joseph M. del Campo, P. B. Ottevanger, Martin Heubner, T. Minarik, Emmanuel Sevin, Nikolaus De Gregorio, M. Bidziński, J. Pfisterer, Susanne Malander, Felix Hilpert, M. R. Mirza, G. ScambiaW. Meier, M.O. Nicoletto, L. Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter, Armando Santoro

Research output: Contribution to journalArticlepeer-review

Cite this